Gilead Sciences' Kite to Acquire Interius BioTherapeutics for $350M, Strengthening CAR Therapeutics Position

Gilead Sciences' Kite unit is acquiring Interius BioTherapeutics for $350M, strengthening its position in in vivo CAR therapeutics. Interius' platform enables the generation of CAR T-cells within the patient's body, potentially leading to more durable and effective treatments. The acquisition will bolster Kite's portfolio and further its goal of developing innovative cancer therapies.

Santa Monica, Calif. & Philadelphia – Gilead Sciences' Kite unit has announced a strategic acquisition of Interius BioTherapeutics for $350 million. The deal aims to bolster Kite's position in in vivo CAR therapeutics, a promising frontier in cancer treatment. Interius' proprietary platform enables the generation of CAR T-cells directly within the patient's body, potentially offering more durable and effective treatments.

Interius' in vivo platform, which eliminates the need for ex vivo engineering, could simplify CAR-T therapy and reduce costs. This approach targets CD20-positive B-cell malignancies by reprogramming CD7-positive T and NK cells within the patient's body. The acquisition aligns with Kite's broader mission to expand its cell therapy portfolio into allogeneic and in vivo platforms, addressing unmet needs in solid tumors and autoimmune diseases.

The acquisition is expected to reduce Gilead's GAAP and non-GAAP 2025 EPS by approximately $0.23-$0.25. The transaction is subject to customary conditions, including the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

References:

[1] https://interiusbio.com/press-release/kite-to-acquire-interius-biotherapeutics-to-advance-in-vivo-platform/

[2] https://www.ainvest.com/news/gilead-kite-acquires-interius-biotherapeutics-strategic-leap-vivo-gene-therapy-2508/